Med-X IPO: revenue, losses and offering terms from its S-1
Med-X filed its S-1 on 25 Sep 2026 to list on Nasdaq as MXRX, and has amended it once. It has not set a price range yet.
Headlines
- Revenue, First half of 2026
- $1M
- Up 16% on a year earlier
- Price range
- Not set yet
Med-X IPO terms
From the newest registration statement. Terms left blank there are not set yet.
- Exchange
- Nasdaq Global Market
- Ticker
- MXRX
- Price range
- Not set yet
- Shares offered
- Not set yet
- Expected to raise
- Not set yet
- Registered
- $158M, the amount the filing fee is paid on
- First filed
- 25 Sep 2026
Med-X revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| First half of 2025 | $885,520 | - | - |
| First half of 2026 | $1M | -$8M | -$8M |
Med-X share structure and company facts
- Share classes and votes
- Class A: 10 votes, Class B: 1 vote
- Headquarters
- Canoga Park, California
Med-X's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Med-X's newest prospectus (S-1/A filed 15 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.